Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-Resistant Fallopian Tube Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04753216
What this trial is testing

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
Northwestern University 3
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Early research (Phase 1)Study completedNCT00692900
What this trial is testing

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
University of Pittsburgh 25
Early research (Phase 1)UnknownNCT04678102
What this trial is testing

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CarcinomaPlatinum-Resistant Fallopian Tube Carcinoma+1 more
Seoul National University Hospital 36
Large-scale testing (Phase 3)Not Yet RecruitingNCT07545460
What this trial is testing

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 404
Testing effectiveness (Phase 2)UnknownNCT03363867
What this trial is testing

BEACON - ABC in Recurrent Platinum Resistant HGSOC

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Peter MacCallum Cancer Centre, Australia 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07591831
What this trial is testing

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian CancerFallopian Tube CancersEpithelial Ovarian Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00022347
What this trial is testing

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT03704467
What this trial is testing

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT01100372
What this trial is testing

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Medical University Innsbruck 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT04781088
What this trial is testing

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+4 more
Floor Backes, MD 38
Testing effectiveness (Phase 2)Study completedNCT03093155
What this trial is testing

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Yale University 78
Early research (Phase 1)Looking for participantsNCT06483048
What this trial is testing

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+13 more
Mayo Clinic 12
Testing effectiveness (Phase 2)Study completedNCT01196559
What this trial is testing

Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
The Catholic University of Korea 44
Testing effectiveness (Phase 2)Study completedNCT00301756
What this trial is testing

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Borderline Ovarian Surface Epithelial-Stromal Tumor+5 more
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Ended earlyNCT02923739
What this trial is testing

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+17 more
M.D. Anderson Cancer Center 9
Large-scale testing (Phase 3)Active Not RecruitingNCT05116189
What this trial is testing

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Who this might be right for
Ovarian CancerCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms
Merck Sharp & Dohme LLC 643
Testing effectiveness (Phase 2)Study completedNCT01283035
What this trial is testing

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Ovarian SarcomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Study completedNCT01652079
What this trial is testing

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Massachusetts General Hospital 63
Not applicableEnded earlyNCT05891197
What this trial is testing

A Biomarker Screening Protocol for Participants With Solid Tumors

Who this might be right for
Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung Cancer+19 more
Lyell Immunopharma, Inc. 10
Next Page